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Bram H. Goldstein1Clinical Practice Points
 Female adnexal tumors of probable wolfﬁan origin are
very rare neoplasms that coincide with abdominal pain
and swelling.
 These lesions are typically considered to be of low
malignant potential, but they are periodically aggres-
sive and can metastasize.
 Immunohistochemistry is not always effective in
determining the clinical diagnosis of these tumors,
and standard treatment is indeterminate.
 This report presents a patient diagnosed with a female
adnexal tumor of probable wolfﬁan origin who
intraoperatively developed incidental disseminated
intravascular coagulation that was successfully
addressed with pressure, microﬁbrillar collagen he-
mostat, and blood products. Regrettably, she died of
disease progression 4 weeks postoperatively.
 Despite the uncharacteristic coexistence of a female
adnexal tumor of probable wolfﬁan origin and
disseminated intravascular coagulation, oncology
surgeons should be prepared for these 2 conditions
in an attempt to confer an optimal patient outcome.Clinical Ovarian and Other Gynecologic Cancer, Vol. 6, No. 1/2, 58-61 ª 2014 Elsevier Inc. All rights reserved.
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Female adnexal tumors of probable wolfﬁan origin were originally
documented in 1973, and since then approximately 86 cases have
been reported in the literature.1,2 Clinically, these neoplasms are
predominantly of low malignant potential, but they can be
aggressive, with a proclivity for distant metastases and disease
progression.3
Grossly, female adnexal tumors of probable wolfﬁan origin are
solid, cystic, or both, and histologically, they contain diffuse
epithelial cells with sieve-like, tubular patterns4; the tumor cells
grow in solid sheets, and may also exhibit a mesenchymal,
spindle cell appearance.5,6 These lesions are immunoreactive for1Gynecologic Oncology Associates, Newport Beach, CA
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Clinical Ovarian and Other Gynecologic Cancer December 2013cytokeratin, inhibin, and vimentin.1,5,6 Nevertheless, because
immunohistochemistry may not necessarily differentiate these ma-
lignancies from sex cordestromal tumors or adenocarcinoma,3,4
patient diagnosis and corresponding therapeutic management
remain indeterminate.
Case Report
A 67-year-old (gravid 1, para 1) woman presented with a pelvic
mass in June 2013. She was taken to the operating room, where-
upon the mass was found to be adherent to the anterior abdominal
wall, omentum, sigmoid colon, left pelvic sidewall, and small in-
testine mesentery. There was discernible metastatic disease in the
pelvis; thus, the decision was made to bisect the friable tumor to
enhance visibility and facilitate resection.
Suddenly, the patient experienced massive intraperitoneal
hemorrhaging, indicative of disseminated intravascular coagulation
(DIC). Initially, direct abdominal pressure was used to stanch the
hemorrhaging. Her international normalized ratio (1.9) and acti-
vated partial thromboplastin time (50 seconds) were signiﬁcantly
prolonged. Moreover, the patient’s ﬁbrinogen level (70 mg/dL)2212-9553/$ - see frontmatter ª 2014 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.cogc.2014.06.005
Figure 1 Representative Low-Power Microscopic View of the
Tumor. Visible is Prominent Biphasic Architecture
With Gland-Like and Spindle Cell Components
(Hematoxylin and Eosin, Original
Magniﬁcation 3100)
Figure 3 Representative Area of the Tumor. Visible Is the
Biphasic Architecture With Gland-Like and Spindle
Cell Components (Hematoxylin and Eosin, Original
Magniﬁcation 3200)was markedly diminished, and she was thrombocytopenic (74,000
cells/mm3).
The patient received 7 units of packed red blood cells, 2 units of
fresh frozen plasma, and 15 units of cryoprecipitate to address the
coagulopathy. Finally, microﬁbrillar collagen hemostat topical
powder and sheets (C.R. Bard Inc, Murray Hill, NJ) were placed on
the bleeding peritoneal surfaces and liberally positioned in the
pelvis; hemostasis was ultimately achieved.
In consideration of the DIC, the omentum and rectal nodules
were not resected. Postoperatively, a 2.5-cm nodule on the anterior
rectum represented the largest amount of residual disease; the esti-
mated blood loss for the procedure was 2600 mL. Once the surgeryFigure 2 Immunohistochemical Staining. Numerous
Immunohistochemical Stains Were Performed,
Showing Patchy Keratin Positivity (Hematoxylin and
Eosin, Original Magniﬁcation 3 100), and There was
Additional Staining for CD10, Calretinin, and PAX8
(Paired Box 8)was concluded, hemostasis was excellent and the patient was in
stable condition.
Immunostaining found that the epithelial cells were positive for
PAX8 (paired box 8) (strong, diffuse), CD10 (multifocal), calretinin
(multifocal), pankeratin, vimentin, CD56, and cytokeratin 7
(CK7). The neoplastic tissue was morphologically biphasic, com-
prising uniform nuclear morphology with epithelial differentia-
tion and an admixture of glandular and prominent spindle
components. Initially, endometrial carcinoma and mesothelioma
were considered, but the CD10, calretinin, and PAX8 ﬁndings were
more indicative of a female adnexal tumor of probable wolfﬁan
origin (Figures 1 to 5).
The patient was discharged and slated to undergo adjuvant
paclitaxel and carboplatin chemotherapy. However, 4 weeksFigure 4 Gland-Like Architecture. High-Power Magniﬁcation
Showing Representative Gland-Like Architecture
Within the Tumor (Hematoxylin and Eosin, Original
Magniﬁcation 3200)
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Figure 5 Malignant Spindle Cell Component. High-Power
Magniﬁcation Showing the Malignant Spindle Cell
Component With High Mitotic Activity (Hematoxylin
and Eosin, Original Magniﬁcation 3200)
Tumors of Wolfﬁan Origin
60 -postoperatively, she experienced acute decompensation, upon
which she was immediately referred to the emergency room and
underwent a laparotomy; the surgical ﬁndings revealed profound,
recurrent malignant tissue throughout the small intestine. In
consideration of the cancer’s recrudescent nature, further surgical
resection was contraindicated; shortly thereafter, the patient died
of her disease.
Discussion
The genital ducts effectuate the transportation of reproductive
cells to a location amenable to fertilization. Embryologically in
males, the emerging gonad contributes to the wolfﬁan ducts’
development and regression of the müllerian ducts.7 Alternatively,
in a female embryo, the müllerian ducts develop and the wolfﬁan
ducts regress. When the female wolfﬁan ducts fail to regress,Table 1 Select Reported Adjuvant Therapies in the Management of
Reference Age (Years) Site
Sivathondan et al4 52 Ovary and broad ligament
Steed et al2 15 Retroperitoneum
Ramirez et al1 38 Pelvis
Sheyn et al5 60 Ovary and broad ligament
Syriac et al6 38 Broad ligament
Atallah et al10 27 Adnexa
Abbreviations: AUC ¼ area under the curve; AWD ¼ alive with disease; DOD ¼ died of disease; N
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(eg, in the ovarian hilum, in the broad ligament, and lateral to the
uterus or vagina).7
This report describes a patient with a female adnexal tumor of
probable wolfﬁan origin whose intraoperative management was
complicated by DIC. DIC is characterized by systemic activation
of blood coagulation, which can severely diminish coagulation
proteins and platelets, resulting in intractable bleeding.8 Clini-
cally, patients with ascites who undergo cytoreductive surgery and
have a preoperative serum albumin less than 3.5 g/dL or metas-
tases greater than 10 cm may be at increased risk for the devel-
opment of a perioperative coagulopathy.9 Interestingly, the
present authors were unable to identify any cases involving these 2
intercurrent conditions, and it is presumed that the DIC was
attributable to the resection and bisection of the large, friable
tumor.
Optimal therapy in the management of female adnexal tumors of
probable wolfﬁan origin remains indeterminate (Table 1).1,2,4-6,10
The disease can be focally hemorrhagic and necrotic, and thus
an attempt should be made to preserve the lesion’s integrity3;
although the data are very limited, surgical management should
resemble the approach to epithelial ovarian malignancies (ie,
staging for disease clinically conﬁned to the ovary and tumor
debulking in patients with advanced-stage disease).1,2 However,
because these malignancies can be aggressive and associated with
progressive disease,3 surgery, adjuvant therapy, and surveillance are
recommended.
Regarding cytotoxic therapy, Steed et al2 reported a 2-year
progression-free interval after cisplatin (75 mg/m2) and cyclophos-
phamide (450 mg/m2) chemotherapy in a patient diagnosed with a
female adnexal tumor of probable wolfﬁan origin. When the patient
developed progressive disease, she was treated with several lines of
chemotherapies, of which imatinib (300 mg) conferred quiescent
disease with 10 months of follow-up.
The reported combinations of cisplatin/cyclophosphamide and
cisplatin/paclitaxel have been associated with a recurrence-free in-
terval ranging from 4 to 61 months,2,5,10 and the present authorsFemale Adnexal Tumors of Probable Wolfﬁan Origin
Management Outcome (mo)
Radiotherapy (3000 cGy) NED, 228
Cisplatin (75 mg/m2),
cyclophosphamide (450 mg/m2),
etoposide (150 mg/m2),
ifosfamide (3 g/m2),
carboplatin (5 AUC),
irinotecan (20 mg/m2),
imatinib (300 mg)
AWD, 76
Paclitaxel (175 mg/m2),
carboplatin (AUC 5)
AWD, 3
Cisplatin (75 mg/m2),
cyclophosphamide (50 mg/m2)
AWD, 61
Imatinib (400 mg) AWD, 42
Cisplatin (NS),
cyclophosphamide (NS),
paclitaxel (NS)
DOD, 52
ED ¼ no evidence of disease; NS ¼ not speciﬁed.
John V. Brown III et alelected to treat this patient with the latter combination. One may
also consider radiotherapy, as this treatment modality has been
associated with a favorable response.4
Immunohistochemical analysis is reasonable if the tumor over-
expresses c-kit (Mast/stem cell growth factor receptor Kit), partic-
ularly because imatinib has reportedly conferred a beneﬁcial, clinical
outcome.2,6 Conversely, if the tumor does not overexpress c-kit,
cisplatin and either paclitaxel or cyclophosphamide chemotherapy
should be a consideration. The strategy would ultimately be
modiﬁed based on the patient’s response, toxicity, and comorbid
history.
Conclusion
Despite the uncharacteristic coexistence of a female adnexal tu-
mor of probable wolfﬁan origin and DIC, oncology surgeons should
be prepared for them in an attempt to confer an optimal patient
outcome.Disclosure
This study was supported by the Nancy Yeary Women’s Cancer
Research Foundation, although the organization was entirelyuninvolved in the research and the preparation of the article. All
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